|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Yang L, Parkin DM, Li L and Chen Y: Time
trends in cancer mortality in China: 1987–1999. Int J Cancer.
106:771–783. 2003.
|
|
3
|
Baczyk M, Czepczynski R, Milecki P,
Pisarek M, Oleksa R and Sowinski J: 89Sr versus 153Sm-EDTMP:
comparison of treatment efficacy of painful bone metastases in
prostate and breast carcinoma. Nucl Med Commun. 28:245–250. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adams GE, Ahmed I, Sheldon PW and
Stratford IJ: RSU 1069, a 2-nitroimidazole containing an alkylating
group: high efficiency as a radio- and chemosensitizer in vitro and
in vivo. Int J Radiat Oncol Biol Phys. 10:1653–1656. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ni X, Zhang Y, Ribas J, et al:
Prostate-targeted radiosensitization via aptamer-shRNA chimeras in
human tumor xenografts. J Clin Invest. 121:2383–2390. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baj G, Arnulfo A, Deaglio S, et al:
Arsenic trioxide and breast cancer: analysis of the apoptotic,
differentiative and immunomodulatory effects. Breast Cancer Res
Treat. 73:61–73. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Qu X, Qu J, et al: Arsenic trioxide
induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit
PI3K/Akt signaling and thereby regulate p53 activation. Cancer
Lett. 284:208–215. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Siu KP, Chan JY and Fung KP: Effect of
arsenic trioxide on human hepatocellular carcinoma HepG2 cells:
inhibition of proliferation and induction of apoptosis. Life Sci.
71:275–285. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ling YH, Jiang JD, Holland JF and
Perez-Soler R: Arsenic trioxide produces polymerization of
microtubules and mitotic arrest before apoptosis in human tumor
cell lines. Mol Pharmacol. 62:529–538. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Davison K, Mann KK and Miller WH Jr:
Arsenic trioxide: mechanisms of action. Semin Hematol. 39:3–7.
2002. View Article : Google Scholar
|
|
11
|
Ai Z, Lu W, Ton S, et al: Arsenic
trioxide-mediated growth inhibition in gallbladder carcinoma cells
via down-regulation of Cyclin D1 transcription mediated by Sp1
transcription factor. Biochem Biophys Res Commun. 360:684–689.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin LM, Li BX, Xiao JB, Lin DH and Yang
BF: Synergistic effect of all-trans-retinoic acid and arsenic
trioxide on growth inhibition and apoptosis in human hepatoma,
breast cancer, and lung cancer cells in vitro. World J
Gastroenterol. 11:5633–5637. 2005.PubMed/NCBI
|
|
13
|
Friesen C, Lubatschofski A, Kotzerke J,
Buchmann I, Reske SN and Debatin KM: Beta-irradiation used for
systemic radioimmunotherapy induces apoptosis and activates
apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging.
30:1251–1261. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xia S, Yu S, Fu Q, et al: Inhibiting
PI3K/Akt pathway increases DNA damage of cervical carcinoma HeLa
cells by drug radiosensitization. J Huazhong Univ Sci Technolog Med
Sci. 30:360–364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giammarile F, Mognetti T and Resche I:
Bone pain palliation with strontium-89 in cancer patients with bone
metastases. Q J Nucl Med. 45:78–83. 2001.PubMed/NCBI
|
|
16
|
Falkmer U, Jarhult J, Wersall P and
Cavallin-Stahl E: A systematic overview of radiation therapy
effects in skeletal metastases. Acta Oncol. 42:620–633. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gkialas I, Iordanidou L, Galanakis I and
Giannopoulos S: The use of radioisotopes for palliation of
metastatic bone pain. J BUON. 13:177–183. 2008.PubMed/NCBI
|
|
18
|
Finlay IG, Mason MD and Shelley M:
Radioisotopes for the palliation of metastatic bone cancer: a
systematic review. Lancet Oncol. 6:392–400. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gunawardana DH, Lichtenstein M, Better N
and Rosenthal M: Results of strontium-89 therapy in patients with
prostate cancer resistant to chemotherapy. Clin Nucl Med. 29:81–85.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rasch-Isla Munoz A and Catano Catano JG:
Usefulness of bone-specific alkaline phosphatase for bone
metastases detection in prostate cancer. Arch Esp Urol. 57:693–698.
2004.(In Spanish).
|
|
21
|
Wetzler M, Brady MT, Tracy E, et al:
Arsenic trioxide affects signal transducer and activator of
transcription proteins through alteration of protein tyrosine
kinase phosphorylation. Clin Cancer Res. 12:6817–6825. 2006.
View Article : Google Scholar
|
|
22
|
Kang SH, Song JH, Kang HK, et al: Arsenic
trioxide-induced apoptosis is independent of stress-responsive
signaling pathways but sensitive to inhibition of inducible nitric
oxide synthase in HepG2 cells. Exp Mol Med. 35:83–90. 2003.
View Article : Google Scholar
|
|
23
|
Xiao YF, Liu SX, Wu DD, Chen X and Ren LF:
Inhibitory effect of arsenic trioxide on angiogenesis and
expression of vascular endothelial growth factor in gastric cancer.
World J Gastroenterol. 12:5780–5786. 2006.PubMed/NCBI
|
|
24
|
Shen ZY, Zhang Y, Chen JY, et al:
Intratumoral injection of arsenic to enhance antitumor efficacy in
human esophageal carcinoma cell xenografts. Oncol Rep. 11:155–159.
2004.PubMed/NCBI
|
|
25
|
Shao QS, Ye ZY, Ling ZQ and Ke JJ: Cell
cycle arrest and apoptotic cell death in cultured human gastric
carcinoma cells mediated by arsenic trioxide. World J
Gastroenterol. 11:3451–3456. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ning S and Knox SJ: Optimization of
combination therapy of arsenic trioxide and fractionated
radiotherapy for malignant glioma. Int J Radiat Oncol Biol Phys.
65:493–498. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park WH, Seol JG, Kim ES, et al: Arsenic
trioxide-mediated growth inhibition in MC/CAR myeloma cells via
cell cycle arrest in association with induction of cyclin-dependent
kinase inhibitor, p21, and apoptosis. Cancer Res. 60:3065–3071.
2000.PubMed/NCBI
|
|
28
|
Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K
and Linn S: Molecular mechanisms of mammalian DNA repair and the
DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Umemura S, Takekoshi S, Suzuki Y, Saitoh
Y, Tokuda Y and Osamura RY: Estrogen receptor-negative and human
epidermal growth factor receptor 2-negative breast cancer tissue
have the highest Ki-67 labeling index and EGFR expression: gene
amplification does not contribute to EGFR expression. Oncol Rep.
14:337–343. 2005.
|
|
30
|
Rupnow BA, Murtha AD, Alarcon RM, Giaccia
AJ and Knox SJ: Direct evidence that apoptosis enhances tumor
responses to fractionated radiotherapy. Cancer Res. 58:1779–1784.
1998.PubMed/NCBI
|
|
31
|
Park JW, Choi YJ, Jang MA, et al: Arsenic
trioxide induces G2/M growth arrest and apoptosis after caspase-3
activation and Bcl-2 phosphorylation in promonocytic U937 cells.
Biochem Biophys Res Commun. 286:726–734. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yih LH, Hsueh SW, Luu WS, Chiu TH and Lee
TC: Arsenite induces prominent mitotic arrest via inhibition of G2
checkpoint activation in CGL-2 cells. Carcinogenesis. 26:53–63.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dai J, Weinberg RS, Waxman S and Jing Y:
Malignant cells can be sensitized to undergo growth inhibition and
apoptosis by arsenic trioxide through modulation of the glutathione
redox system. Blood. 93:268–277. 1999.PubMed/NCBI
|
|
34
|
Middleton G, Cox SW, Korsmeyer S and
Davies AM: Differences in Bcl-2- and Bax-independent function in
regulating apoptosis in sensory neuron populations. Eur J Neurosci.
12:819–827. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li L, Story M and Legerski RJ: Cellular
responses to ionizing radiation damage. Int J Radiat Oncol Biol
Phys. 49:1157–1162. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gupta S, Yel L, Kim D, Kim C, Chiplunkar S
and Gollapudi S: Arsenic trioxide induces apoptosis in peripheral
blood T lymphocyte subsets by inducing oxidative stress: a role of
Bcl-2. Mol Cancer Ther. 2:711–719. 2003.PubMed/NCBI
|
|
37
|
Cory S, Huang DC and Adams JM: The Bcl-2
family: roles in cell survival and oncogenesis. Oncogene.
22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu L, Yang D, Wang S, et al: (−)-Gossypol
enhances response to radiation therapy and results in tumor
regression of human prostate cancer. Mol Cancer Ther. 4:197–205.
2005.
|
|
39
|
Anai S, Goodison S, Shiverick K, Hirao Y,
Brown BD and Rosser CJ: Knock-down of Bcl-2 by antisense
oligodeoxynucleotides induces radiosensitization and inhibition of
angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer
Ther. 6:101–111. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shore GC and Viallet J: Modulating the
Bcl-2 family of apoptosis suppressors for potential therapeutic
benefit in cancer. Hematology Am Soc Hematol Educ Program. 226–230.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chou JJ, Li H, Salvesen GS, Yuan J and
Wagner G: Solution structure of BID, an intracellular amplifier of
apoptotic signaling. Cell. 96:615–624. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kumagai T, Shih LY, Hughes SV, et al:
19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue),
combined with arsenic trioxide, has potent antitumor activity
against myeloid leukemia. Cancer Res. 65:2488–2497. 2005.
View Article : Google Scholar
|
